期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

负荷剂量邦罗力在肺癌骨转移治疗中的应用 被引量：4

Loading-dose ibandronate in the management of symptomatic skeletal metastases due to lung cancer
下载PDF
导出
摘要 转移性骨病（Metastatic Bone Disease,MBD）是肺癌患者常见的严重并发症,影响患者的生活质量,且预后较差。依班膦酸盐（邦罗力）是第三代双膦酸盐化合物,是临床上最强的破骨细胞活性抑制剂。连续三天负荷剂量邦罗力治疗是快速缓解MBD患者疼痛的理想方案。
作者 王季颖 蔡勇
机构地区 上海市肺科医院肿瘤科
出处 《中国肺癌杂志》 CAS 2008年第2期290-291,共2页 Chinese Journal of Lung Cancer
关键词 转移性骨病 转移治疗 负荷剂量 肺癌患者 第三代双膦酸盐 破骨细胞活性 严重并发症 依班膦酸盐
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Pecherstorfer M.Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.Expert Opin Pharmacother,2004,5(11):2341-2350.
  • 2Body JJ,Diel IJ,Lichinitser MR,Kreuser ED,et al.Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.Ann Oncol,2003,14(9):1399-1405.
  • 3Pendharkar D,Goyal H.Loading dose ibandronate in rapid pain management of metastatic bone disease (MBD).J Clin Oncol,2006,24(18S):18580.
  • 4Pecherstorfer M,Rivkin S,Body JJ,et al.Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer:an open-lahel trial.Clin Drug Investig,2006,26(6):315-322.
  • 5Heidenreich A,Ohlmann C,Olbert P,et al.High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer.EurJ Cancer,2003,1:S270.

同被引文献26

  • 1吕媛,权菊香.小牛血清去蛋白注射液对脑细胞缺血缺氧的保护作用及临床应用[J].中国临床药理学杂志,2006,22(2):141-144. 被引量：83
  • 2Decoster L, de Marinis F, Syrigos K, et al. Bisphosphonates : prevention of bone metastases in lung cancer [ J ]. Recent Results Cancer Res,2012,192:93 - 108.
  • 3International Agency for Research on Cancer. GLOBO -CAN 2012: Estimated Cancer Incidence, Mortal ity and Prevalence Worldwide in 2012[ EB/OL]. [ 2016 - 01 - 21 ] http://globocan, iarc. fr/De- fault, aspx.
  • 4Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone me- tastases :an ASTRO evidence-based guideline[ J]. Int J Radiat Oncol Biol Phys,2011,79 (4) :965 - 976.
  • 5NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addi- tion to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual pa- tient data from 16 randomized controlled trials [ J]. J Clin Oncol, 2008,26(28) :4617 -4625.
  • 6Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases : a systematic review [ J]. J Clin Oncol, 2007,25 ( 11 ) : 1423 - 1436.
  • 7Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung canc- er, version 2. 2013 [ J ]. J Natl Compr Canc Netw, 2013,11 (6) :645 - 653.
  • 8Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone me- tastases : an ASTRO evidence-based guideline [ J ]. Int J Radiat Oneol Biol Phys,2011,79(4) :965 -976.
  • 9Caspar W. Actovegin in myelopathies. Clinical experiences with acto- vegin in spinal cord disorders due to compression and circulation problems [ J ]. Fortschr Med, 1978,96 ( 16 ) :887 - 888.
  • 10Veri A,D'Andrea MR,Bonginelli P, et al. Clinical usefulness of bi- sphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers [ J ]. Int J Biol Mark- ers ,2007,22( 1 ) :24 - 33.

引证文献4

二级引证文献218

中国肺癌杂志
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部